Nurix Therapeutics (NASDAQ:NRIX) Trading Down 3.2%

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) fell 3.2% during mid-day trading on Friday . The company traded as low as $23.66 and last traded at $23.66. 45,936 shares were traded during trading, a decline of 95% from the average session volume of 914,554 shares. The stock had previously closed at $24.44.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, May 15th. Stephens assumed coverage on shares of Nurix Therapeutics in a research note on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target on the stock. Royal Bank of Canada lifted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. Needham & Company LLC lowered their target price on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, July 12th. Finally, Robert W. Baird initiated coverage on shares of Nurix Therapeutics in a report on Friday. They issued an “outperform” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.00.

Nurix Therapeutics Trading Down 4.5 %

The business’s fifty day simple moving average is $22.16 and its 200 day simple moving average is $17.43. The stock has a market cap of $1.15 billion, a P/E ratio of -7.99 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The business had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. On average, analysts predict that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the transaction, the chief financial officer now directly owns 31,002 shares in the company, valued at approximately $781,870.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Houte Hans Van sold 20,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the sale, the chief financial officer now directly owns 31,002 shares in the company, valued at approximately $781,870.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Ring sold 9,050 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $24.94, for a total transaction of $225,707.00. Following the completion of the sale, the insider now owns 24,592 shares in the company, valued at $613,324.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,715 shares of company stock worth $1,449,070. Company insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently modified their holdings of NRIX. Quest Partners LLC acquired a new stake in shares of Nurix Therapeutics in the 4th quarter valued at approximately $59,000. GAMMA Investing LLC increased its stake in Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Nurix Therapeutics during the 1st quarter worth approximately $123,000. China Universal Asset Management Co. Ltd. increased its stake in Nurix Therapeutics by 67.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after purchasing an additional 3,793 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in Nurix Therapeutics during the 4th quarter worth approximately $158,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.